Adding a MET gene inhibitor enhances the effect of combined chemotherapy and immunotherapy in small cell lung cancer (SCLC), ...

Bayer and Kumquat Biosciences Inc., a clinical-stage biotech company founded by pioneers of the KRAS pathway, today announced ...

The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced ...

Phase III data show Hernexeos can elicit a confirmed objective response rate of 48% in patients with HER2-mutated NSCLC who had previously been treated with a directed antibody-drug conjugate.

Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to ...

The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combinat ...

The US Food & Drug Administration's (FDA) resources have been cut more times than Martin Scorsese’s then-edgy 1988 religious ...

From medicines from snake venom to supercrops and plastic-eating enzymes. Nine researchers from Leiden University will receive Open Competition XS ...

A new study reveals how Lactococcus lactis (L. lactis), a common food bacterium, regulates the production of a key precursor ...

Booking Health, a global leader in medical treatment coordination, today unveiled a new study titled Role of Immunotherapy in ...

Combining approximately $120 million from the former Helix II trust account (reflecting a final redemption rate of approximately 39% which is the second lowest redemption rate for a biotech de-SPAC ...

Reiterating timelines for FDA submission in 2025Transplant clinical trial has attracted leading transplant hospitalsBooked ...